Department of Radiology and Imaging Sciences
Matthew S. Zabriskie has not added Biography.
If you are Matthew S. Zabriskie and would like to personalize this page please email our Author Liaison for assistance.
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Blood Nov, 2011 | Pubmed ID: 21908430
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Cancer cell Dec, 2011 | Pubmed ID: 22169110
Pushing the limits of targeted therapy in chronic myeloid leukaemia.
Nature reviews. Cancer Jul, 2012 | Pubmed ID: 22825216
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Blood Jan, 2013 | Pubmed ID: 23223358
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
Cancer research Jun, 2013 | Pubmed ID: 23576564
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.
Cancer cell Sep, 2014 | Pubmed ID: 25132497
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Leukemia Mar, 2015 | Pubmed ID: 25134459
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Blood Mar, 2015 | Pubmed ID: 25573989
Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.
Leukemia Sep, 2015 | Pubmed ID: 25676420
A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.
Leukemia Aug, 2015 | Pubmed ID: 25721898
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Experimental hematology Jul, 2015 | Pubmed ID: 25912019
A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research May, 2016 | Pubmed ID: 26673800
Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
Leukemia Dec, 2017 | Pubmed ID: 28819281
A novel fusion in pediatric T-cell acute lymphoblastic leukemia.
Haematologica Feb, 2018 | Pubmed ID: 29284681
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Cancer cell Oct, 2019 | Pubmed ID: 31543464
Apolipoprotein E knockout rabbit model of intracranial atherosclerotic disease.
Animal models and experimental medicine Jun, 2020 | Pubmed ID: 32613180
Rabbit models of intracranial atherosclerotic disease for pathological validation of vessel wall MRI.
The neuroradiology journal Jun, 2021 | Pubmed ID: 33325806
SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.
Blood cancer discovery May, 2021 | Pubmed ID: 34027418
MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.
Blood Feb, 2022 | Pubmed ID: 34780648
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유